Malaria's leftover pigment blocks vaccines—but mRNA fixes it
This week brought major advances in mRNA delivery systems, from cancer vaccines to genetic disease treatments. Researchers are pushing beyond COVID-19 applications to tackle everything from malaria to heart conditions.
🦠 Malaria's leftover pigment blocks vaccines—but mRNA fixes it
Scientists discovered that haemozoin (malarial pigment left in the body after blood-stage malaria) impairs how well traditional malaria vaccines work by blocking dendritic cells from taking up antigens
When they tested an mRNA vaccine encoding malaria T cell targets in mice previously exposed to Plasmodium, it overcame this blockade and restored protection
The combination of traditional radiation-attenuated sporozoites plus mRNA vaccine enhanced liver-resident memory T cells and provided better protection than either approach alone
Why it matters: This explains why malaria vaccines often fail in endemic regions where people have been previously infected, and shows mRNA technology could solve this long-standing problem.
Key Findings
🧬 Large lipid nanoparticles with less PEG target immune cells better
Researchers created oversized lipid nanoparticles (LLNPs) by reducing PEG content to 0.3% and increasing other components sixfold compared to standard formulations
These LLNPs achieved ~82% of GFP-positive cells identified as dendritic cells and ~44% of all dendritic cells expressing the delivered gene
In cancer vaccine tests, LLNPs triggered effective tumor regression at doses as low as 1 μg of mRNA
💊 Gene therapy shows promise for inherited heart disease
Scientists used mRNA in lipid nanoparticles to deliver three genes (COL4A3, COL4A4, COL4A5) that produce kidney filtration proteins in mice with Alport syndrome
The treatment significantly reduced protein leakage in urine and blood urea nitrogen levels
Protection was maintained as long as injections continued, but efficacy was lost when therapy stopped
🔬 Low glucose blocks mRNA therapy effectiveness
Researchers found that low-glucose conditions significantly reduced mRNA translation into protein in multiple cell types using two different lipid nanoparticle formulations
The problem wasn't with cellular uptake or lysosomal escape, but with reduced ATP and GTP levels needed for protein synthesis
Mouse tumor models confirmed that hypoglycemia diminished mRNA delivery efficiency in living animals
🩸 COVID booster changes immune response patterns
Analysis of 36 fully vaccinated individuals showed distinct protein profiles in blood plasma after booster vaccination when exposed to SARS-CoV-2 spike protein
Post-booster recipients exhibited significant activation of complement cascade, platelet degranulation, and blood coagulation pathways
The study identified abundant signatures associated with stress responses and innate immunity that weren't present before the booster
🫁 Liver protein therapy reduces lung scarring
Scientists delivered mRNA encoding ornithine transcarbamylase (OTC), a liver enzyme, using lipid nanoparticles in multiple mouse models of liver fibrosis
The treatment significantly inhibited collagen deposition and recovered impaired mitochondrial function in hepatocytes
When combined with the drug Resmetirom, it showed potent effects against metabolic liver disease with fibrosis
🧪 Silicone oil from syringes affects mRNA vaccine stability
Testing mRNA vaccines stored with silicone oil (used to lubricate prefilled syringes) showed that RNA structure matters for stability
Simple poly-A RNA particles grew larger and became less uniform at 25°C with silicone oil, while complex eGFP-mRNA particles remained stable
Surprisingly, silicone oil partially protected against light-induced damage, improving transfection efficiency by up to 6-fold in some samples
Implications
These studies show mRNA technology expanding far beyond COVID vaccines into cancer treatment, genetic diseases, and organ-specific therapies. However, they also reveal important limitations—from glucose dependence to storage challenges—that researchers are actively working to solve.
Studies in this issue
Primary sources used for this newsletter.
- mRNA vaccination may overcome malaria vaccine problems caused by parasite pigment in micemain storyNature microbiology2026-02-02PMID 41629565
- How Silicone Oil and Storage Conditions Affect the Physical and Functional Stability of mRNA Nanoparticles, Highlighting the Importance of mRNA Structurekey findingMolecular pharmaceutics2026-02-06PMID 41645492
- Lipid nanoparticles carrying ornithine transcarbamylase mRNA reduce liver scarring in animal modelskey findingHepatology (Baltimore, Md.)2026-02-03PMID 41632884
- Changes in Blood Proteins Before and After Pfizer/BNT162b2 Booster Vaccination Show Different Responses to Coronavirus Spike Proteinkey findingJournal of proteome research2026-02-03PMID 41631862
- mRNA Treatment for Alport Syndromekey findingbioRxiv : the preprint server for biology2026-02-06PMID 41648584
- Large and low-PEG lipid nanoparticles improve delivery to immune cells for strong mRNA cancer vaccineskey findingJournal of controlled release : official journal of the Controlled Release Society2026-02-04PMID 41638492
- How Low Blood Sugar Affects mRNA Delivery by Fat-Based Nanoparticles and Whykey findingMolecular pharmaceutics2026-02-02PMID 41627893
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.